Ilamycin B1
General Information
DRACP ID DRACP00778
Peptide Name Ilamycin B1
Sequence XXLXAXX
Sequence Length 7
UniProt ID Not available
PubChem CID Not available
Origin Streptomyces atratus SCSIO ZH16
Type Native peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
HeLa | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | IC50>50µM | MTT assay | Not available | 1 |
HepG2 | Hepatoblastoma | Blastoma | IC50>50µM | MTT assay | Not available | 1 |
A549 | Lung adenocarcinoma | Carcinoma | IC50>50µM | MTT assay | Not available | 1 |
CNE2 | unknow | Carcinoma | IC50>50µM | MTT assay | Not available | 1 |
MCF-7 | Invasive breast carcinoma of no special type | Carcinoma | IC50>50µM | MTT assay | Not available | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HL-7702 (L02): IC50>50µM; HUVEC: IC50>50µM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antibacterial
Structure Information
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond NCB: X1<--->X7
N-terminal Modification Free
C-terminal Modification Free
Other Modification X(1)=Pre-Trp; X(2)=(2S)-2-Aminohex-4-enoic acid; X(4)=METH-Leu; X(6)=N-Tyr; X(7)=METH-Leu
Chiral L
Physicochemical Information
Formula C9H8N2O-2
Absent amino acids CDEFGHIKMNPQRSTVWY
Common amino acids X
Mass 76938
Pl 6.11
Basic residues 0
Acidic residues 0
Hydrophobic residues 2
Net charge 0
Boman Index 673
Hydrophobicity 80
Aliphatic Index 70
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 0
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 28855504
Title Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents
Doi 10.1038/s41467-017-00419-5
Year 2017
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available